Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
27.25
+0.27 (+1.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Best Stocks To Buy Now: June 02, 2022
June 02, 2022
The stock market continues to be one of the best ways for regular investors to build wealth over time. The
Via
Best Stocks
Topics
Artificial Intelligence
Cannabis
Exposures
Artificial Intelligence
Cannabis
Sarissa Condemns Poor Corporate Governance at Alkermes
May 27, 2022
From
Sarissa Capital Management LP
Via
Business Wire
New Findings About Life With Bipolar 1 Disorder
May 27, 2022
SOURCE: Alkermes
Via
3BL Media
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
May 26, 2022
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...
Via
FinancialNewsMedia
Exposures
COVID-19
Recap: Alkermes Q1 Earnings
April 27, 2022
Alkermes (NASDAQ:ALKS) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Treating Bipolar 1 Disorder
May 24, 2022
SOURCE: Alkermes
Via
3BL Media
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
May 22, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing...
Via
Talk Markets
Alkermes Awarded 2022 Platinum Bell Seal for Workplace Mental Health
May 19, 2022
SOURCE: Alkermes
Via
3BL Media
Tips to Improve Mental Well-Being
May 17, 2022
SOURCE: Alkermes
Via
3BL Media
Alkermes Celebrates National Women's Health Week by Reminding You Why Regular Cancer Screenings Are Vital
May 13, 2022
SOURCE: Alkermes
Via
3BL Media
Expert Ratings for Alkermes
April 21, 2022
Alkermes (NASDAQ:ALKS) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
May 06, 2022
SOURCE: Alkermes
Via
3BL Media
Looking Into Alkermes's Return On Capital Employed
April 28, 2022
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter.
Via
Benzinga
61 Biggest Movers From Yesterday
April 28, 2022
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with...
Via
Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
April 27, 2022
Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of...
Via
Benzinga
LGBTQ+ People Are More Likely to Experience a Mental Health Condition
April 27, 2022
SOURCE: Alkermes
Via
3BL Media
Topics
LGBTQ
Exposures
Diversity
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Alkermes's Earnings Outlook
April 26, 2022
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will...
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
Alkermes Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 22, 2022
Alkermes (NASDAQ:ALKS) will host a conference call at 08:00 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. How to Attend Alkermes (ALKS) Conference Call Follow this link to access the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022
April 20, 2022
Upgrades
Via
Benzinga
Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen
April 19, 2022
Via
Benzinga
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital
March 31, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States,...
Via
Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
March 24, 2022
Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
March 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops
March 14, 2022
Sentiment was low heading into the study and analysts aren't hopeful for other tests.
Via
Investor's Business Daily
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
March 08, 2022
Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric...
Via
FinancialNewsMedia
Topics
Economy
Exposures
Economy
The Ruble Is Rubble
March 03, 2022
MSCI says Russian companies are
Via
Talk Markets
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer
February 17, 2022
Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.